Clinical Trials Advisor

Oct. 25, 2012 | Vol. 17 No. 21

EMA Proposes Co-Primary Endpoints in Acute Heart Failure Drug Trials

Developers of acute heart failure drugs should conduct double-blind, randomized Phase III trials with co-primary endpoints, rather than composite endpoints, according to a European Medicines Agency (EMA) draft guideline.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

GHTF Issues Final Guidance on Clinical Evidence for IVDs in One of Last Acts Acute Heart Failure Drug Trials Should Include Co-Primary Endpoints, EMA Says Japan: PMDA Notice Shows Increasing Willingness to Accept Global Clinical Trials EMA Releases Guideline on Trials of Drugs to Prevent Strokes, SEEs

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.